CDK9 and neoplasm: The relationship between CKD9 and MYC has clinical ramifications: the high dependency of MYC-driven tumours on CDK9 render them more sensitive to CDK9 inhibitors [130], a concept that is being harnessed in clinical trials of these drugs whereby patients are selected for treatment based on MYC amplification status (see Table 2 and below for more detail).